US pharma giant Pfizer’s executive chairman Ian Read has chosen to retire on December 31, 2019.
As a result, the Pfizer board of directors says it has unanimously elected its chief executive Dr Albert Bourla, to succeed him as chairman effective January 1, 2020.
Dr Bourla will also retain the CEO role, which he inherited at the start of this year from Mr Reed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze